Samantha L. Savage Stevens

TL;DR: Together, these findings suggest that combined BCR-ABL1 kinase inhibition and protein degradation may represent a strategy to address B CR-ABl1-dependent drug resistance, and warrants further investigation into the eradication of persistent leukemic stem cells, which rely on neither the presence nor the activity of the BCR/F3 protein for survival.

TL;DR: It is demonstrated that combining asciminib with ATP site TKIs enhances target inhibition and suppression of resistant outgrowth in Ph+ clinical isolates and cell lines and restores ponatinib's effectiveness against currently untreatable compound mutants at clinically achievable concentrations.

TL;DR: Ruxolitinib was well tolerated and demonstrated an estimated response rate of 32%, and patients with a diagnosis of CNL and/or harboring CSF3R-T618I were most likely to respond.

TL;DR: NT157 has antineoplastic effects on BCR-ABL1 leukemogenesis, independent of T315I mutational status, and significantly reduced colony formation of human primary CML cells with minimal effect on normal hematopoietic cells.